2次性脳卒中予防に対するクロピドグレルの影響

Bruce Ovbiagele¹, Jing Wang¹, S Claiborne Johnston¹+5

• ¹From Department of Neurology, Medical University of South Carolina, Charleston (B.O.); Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China (J.W., A.W., Y.W., X.Z., Y.W.); China National Clinical Research Center for Neurological Diseases, Beijing (J.W., A.W., Y.W., X.Z., Y.W.); Center of Stroke, Beijing Institute for Brain Disorders, China (J.W., A.W., Y.W., X.Z., Y.W.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China (J.W., A.W., Y.W., X.Z., Y.W.); Beijing Key Laboratory of Central Nervous System Injury, China (J.W., A.W., Y.W., X.Z., Y.W.); The University of Texas, Dell Medical School, Austin (S.C.J.); and INI Stroke Network, OSF Healthcare System, University of Illinois College of Medicine, Peoria (D.W.).+1